8/13/26
AELIS FARMA (AELIS.PA) Thesis: Concerns over cash burn and increasing competition are overshadowing positive clinical trial results, leading to a more cautious investor sentiment.
★ Analysts see FY2026 revenue reaching $12M — +495% growth in a single year.
What Moves the Stock 1 Progress in clinical trials for lead drug candidates such as AELIS-001 2 Partnership announcements with larger pharmaceutical companies 3 Regulatory approvals from health authorities 4 Market sentiment towards the biotechnology sector 5 Therapeutic product sales - 0% 6 Research collaborations - 0% 7 Grants and funding - 0% 8 Increased focus on mental health treatments 0.9 1.1 1.4 1.6 1.8 1.05 AELIS.PA Daily 1.05 Mar '26 May '26 Jun '26 Aug '26
My Notes "Investors are increasingly worried about the sustainability of Aelis's operations amid rising competition." Moat: Aelis Farma's proprietary technology offers a unique approach to CNS disorders… growth - Investors looking for high-risk, high-reward opportunities in biotechnology. Interest rates affect Aelis Farma primarily through the cost of financing its operations. Watch on earnings: Clinical trial success rates, Funding and partnership announcements, Cash runway (months until funding runs out). One Sentence Summary: Aelis Farma: the story is balanced — progress in clinical trials for lead drug candidates such as aelis-001.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.